United Therapeutics CEO sells 1,920 shares

Q: How many UTHR shares did Martine A. Rothblatt sell, and at what prices?

Martine A. Rothblatt reported sales of 1,920 United Therapeutics common shares on September 30, 2026, through family trusts. The reported weighted-average prices were $547.2940 for 400 shares, $548.2529 for 280, $549.3977 for 240, $550.4675 for 400, $551.4950 for 160, $552.6267 for 120, $553.7787 for 113, and $554.6997 for 207.

Q: What are the terms of the UTHR trading plan covering these sales?

The sales were reported under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The plan continues until the earlier of exercise of 1,734,410 stock options, all of which expire March 15, 2027, or December 31, 2026.

The pre-arranged Rule 10b5-1 plan continues until the earlier of a stated stock-option exercise threshold or December 31, 2026.

Filing Impact

(Very High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported sales of 1,920 common shares on September 30, 2026, through family trusts in which she shares investment power. The eight reported weighted-average prices ranged from $547.2940 to $554.6997 per share. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.

Insights

Analyzing...

Insider Trade Summary 10b5-1

Net Seller: 1,920 shares

Net Sell 13 txns

Insider ROTHBLATT MARTINE A

Role Chairperson & CEO

Sold 1,920 shs ($1.06M)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2, F3}	400	$547.294	$219K
Sale	Common Stock ^{F1, F4, F3}	280	$548.2529	$154K
Sale	Common Stock ^{F1, F5, F3}	240	$549.3977	$132K
Sale	Common Stock ^{F1, F6, F3}	400	$550.4675	$220K
Sale	Common Stock ^{F1, F7, F3}	160	$551.495	$88K
Sale	Common Stock ^{F1, F8, F3}	120	$552.6267	$66K
Sale	Common Stock ^{F1, F9, F3}	113	$553.7787	$63K
Sale	Common Stock ^{F1, F10, F3}	207	$554.6997	$115K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock ^F11	--	--	--
holding	Common Stock ^F12	--	--	--
holding	Common Stock ^F13	--	--	--

Holdings After Transaction: Common Stock — 628,049 shares (Indirect, by Trust); Common Stock — 40,513 shares (Direct); Common Stock — 166 shares (Indirect, by Spouse)

Footnotes (13)

F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
F10. This transaction was executed in multiple trades at prices ranging from $554.21 to $555.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F12. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F13. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F2. This transaction was executed in multiple trades at prices ranging from $546.91 to $547.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F4. This transaction was executed in multiple trades at prices ranging from $547.94 to $548.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5. This transaction was executed in multiple trades at prices ranging from $549.01 to $549.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6. This transaction was executed in multiple trades at prices ranging from $550.04 to $551.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7. This transaction was executed in multiple trades at prices ranging from $551.17 to $551.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8. This transaction was executed in multiple trades at prices ranging from $552.21 to $553.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9. This transaction was executed in multiple trades at prices ranging from $553.21 to $554.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Reported weighted-average sale price: $547.2940 per share for 400 shares Reported weighted-average sale price: $548.2529 per share for 280 shares Reported weighted-average sale price: $549.3977 per share for 240 shares +5 more

8 metrics

Reported weighted-average sale price $547.2940 per share for 400 shares September 30, 2026; family trust

Reported weighted-average sale price $548.2529 per share for 280 shares September 30, 2026; family trust

Reported weighted-average sale price $549.3977 per share for 240 shares September 30, 2026; family trust

Reported weighted-average sale price $550.4675 per share for 400 shares September 30, 2026; family trust

Reported weighted-average sale price $551.4950 per share for 160 shares September 30, 2026; family trust

Reported weighted-average sale price $552.6267 per share for 120 shares September 30, 2026; family trust

Reported weighted-average sale price $553.7787 per share for 113 shares September 30, 2026; family trust

Reported weighted-average sale price $554.6997 per share for 207 shares September 30, 2026; family trust

Key Terms

pre-arranged 10b5-1 trading plan, weighted average price, investment power

3 terms

pre-arranged 10b5-1 trading plan regulatory

"pursuant to a pre-arranged 10b5-1 trading plan"

weighted average price financial

"price reported above reflects the weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

investment power regulatory

"shares investment power and the Reporting Person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many UTHR shares did Martine A. Rothblatt sell, and at what prices?

Martine A. Rothblatt reported sales of 1,920 United Therapeutics common shares on September 30, 2026, through family trusts. The reported weighted-average prices were $547.2940 for 400 shares, $548.2529 for 280, $549.3977 for 240, $550.4675 for 400, $551.4950 for 160, $552.6267 for 120, $553.7787 for 113, and $554.6997 for 207.

What are the terms of the UTHR trading plan covering these sales?

The sales were reported under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The plan continues until the earlier of exercise of 1,734,410 stock options, all of which expire March 15, 2027, or December 31, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/01/2026 - 05:22 PM Accepted by SEC EDGAR 10/01/2026 - 05:22 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROTHBLATT MARTINE A

(Last)

(First)

(Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING

MARYLAND

20910

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairperson & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/30/2026		S⁽¹⁾		400	D	$547.294⁽²⁾	325,963	I	by Trust⁽³⁾
Common Stock	09/30/2026		S⁽¹⁾		280	D	$548.2529⁽⁴⁾	325,683	I	by Trust⁽³⁾
Common Stock	09/30/2026		S⁽¹⁾		240	D	$549.3977⁽⁵⁾	325,443	I	by Trust⁽³⁾
Common Stock	09/30/2026		S⁽¹⁾		400	D	$550.4675⁽⁶⁾	325,043	I	by Trust⁽³⁾
Common Stock	09/30/2026		S⁽¹⁾		160	D	$551.495⁽⁷⁾	324,883	I	by Trust⁽³⁾
Common Stock	09/30/2026		S⁽¹⁾		120	D	$552.6267⁽⁸⁾	324,763	I	by Trust⁽³⁾
Common Stock	09/30/2026		S⁽¹⁾		113	D	$553.7787⁽⁹⁾	324,650	I	by Trust⁽³⁾
Common Stock	09/30/2026		S⁽¹⁾		207	D	$554.6997⁽¹⁰⁾	324,443	I	by Trust⁽³⁾
Common Stock								40,513	D
Common Stock								166	I	by Spouse
Common Stock								249,108	I	by Trust⁽¹¹⁾
Common Stock								45,596	I	by Trust⁽¹²⁾
Common Stock								8,902	I	by Trust⁽¹³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.

2. This transaction was executed in multiple trades at prices ranging from $546.91 to $547.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

4. This transaction was executed in multiple trades at prices ranging from $547.94 to $548.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $549.01 to $549.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $550.04 to $551.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $551.17 to $551.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $552.21 to $553.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $553.21 to $554.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $554.21 to $555.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

11. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

12. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

13. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

Remarks:

Due to the 30 line limitation in Table I, this report is being filed across two forms. This is the second of two filings.

	/s/ John S. Hess, Jr. under Power of Attorney	10/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR